Cargando…

P079 Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation

Detalles Bibliográficos
Autores principales:	Vincken, S., Knoop, C., Verbanck, S., Buyck, N., Vanderhelst, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Cystic Fibrosis Society. 2022
Materias:	Poster Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184784/ http://dx.doi.org/10.1016/S1569-1993(22)00412-X

Ejemplares similares

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
por: Comegna, Marika, et al.
Publicado: (2021)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
por: Salvatore, Donatello, et al.
Publicado: (2021)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

Decoding F508del Misfolding in Cystic Fibrosis
por: Wang, Xiaodong Robert, et al.
Publicado: (2014)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report
por: Welsner, Matthias, et al.
Publicado: (2019)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
por: Zemanick, Edith T., et al.
Publicado: (2021)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
por: Mall, Marcus A., et al.
Publicado: (2022)

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
por: Griese, Matthias, et al.
Publicado: (2021)

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N
por: Berkhout, Maaike, et al.
Publicado: (2015)

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR
por: Rayment, Jonathan H., et al.
Publicado: (2022)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
por: Esposito, Speranza, et al.
Publicado: (2016)

P.F508del editing in cells from cystic fibrosis patients
por: Smirnikhina, Svetlana A., et al.
Publicado: (2020)

Case report: Three adult brothers with cystic fibrosis (delF508-delF508) maintain unusually preserved clinical profile in the absence of standard CF care
por: Bishop, Clark T.
Publicado: (2021)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis,
por: Marson, Fernando Augusto de Lima, et al.
Publicado: (2013)

Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients
por: Melotti, Paola, et al.
Publicado: (2014)

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
por: Sermet-Gaudelus, Isabelle, et al.
Publicado: (2018)

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del
por: Beswick, Daniel M., et al.
Publicado: (2022)

Two Siblings Homozygous for F508del-CFTR Have Varied Disease Phenotypes and Protein Biomarkers
por: Zhang, Zhihong, et al.
Publicado: (2021)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial
por: Stahl, Mirjam, et al.
Publicado: (2023)

Correctors modify the bicarbonate permeability of F508del-CFTR
por: Fiore, Michele, et al.
Publicado: (2020)

Q1291H-CFTR molecular dynamics simulations and ex vivo theratyping in nasal epithelial models and clinical response to elexacaftor/tezacaftor/ivacaftor in a Q1291H/F508del patient
por: Allan, Katelin M., et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice
por: Dhooghe, Barbara, et al.
Publicado: (2015)

L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
por: Lo Cicero, Stefania, et al.
Publicado: (2023)

Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis
por: Horn, Tabea, et al.
Publicado: (2020)

Variability of Clinical Presentation in Patients Heterozygous for the F508del Cystic Fibrosis Variant: A Series of Three Cases and a Review of the Literature
por: Raymond, Caitlin M, et al.
Publicado: (2023)

Structural Comparative Modeling of Multi-Domain F508del CFTR
por: McDonald, Eli Fritz, et al.
Publicado: (2022)

Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
por: Lo Cicero, Stefania, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dfh5mu23bc3q3umj39rbe1alcn